Bing Center for Waldenstrom's Macroglobulinemia
April 9, 2015, BOSTON, MA – The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom’s Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.
The median overall response rate was 91 percent after a median of 19 months of treatment, and in 69 percent of patients the cancer had not worsened two years after beginning treatment. When the cancer did progress, began at a median time of 9.6 months after the start of treatment. The results are reported in New England Journal of Medicine.
SUNNYVALE, Calif., Jan. 29, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA® (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indolent type of B-cell lymphoma.1 This is the fourth indication for IMBRUVICA, an oral therapy, which received FDA Breakthrough Therapy Designation for this indication in February 2013.
The WM Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Plasma cell regulatory pathways in WM. In recent studies, we have attempted to dissect the molecular mechanisms which prevent WM cells from fully differentiating into plasma cells. Ordinarily, B-cells mature in a defined manner passing through the mature B-cell stage to lymphoplasmacytic cells, and then onto mature plasma cells. Mature plasma cells make antibodies that serve to protect us against pathogens, and typically include the IgA and IgG antibodies.